SCHEMBL415966

SCHEMBL415966

COC(=O)c1cc(Cl)ccc1NC(=O)Cn1ccc2cc(-c3ccccc3)ccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.54
NTSR1 P30989 6/20 0.53
ALDH1A1 P00352 3/20 0.47
GAA P10253 3/20 0.47
HSD17B10 Q99714 1/20 0.47
RXFP1 Q9HBX9 1/20 0.46
SERPINE1 P05121 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KDM4E B2RXH2 2/20 0.43
LMNA P02545 2/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
NR4A2 P43354 1/20 0.43
POLB P06746 1/20 0.42
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420811 0.90 SERPINE1 (0.55) MAPTNTSR1ALDH1A1GAAHSD17B10
SCHEMBL418089 0.85 NTSR1 (0.49) MAPTNTSR1ALDH1A1GAAHSD17B10
SCHEMBL420932 0.78 MEN1 (0.57) ALDH1A1GAASERPINE1SMN1; SMN2CYP1A2
SCHEMBL419152 0.77 MAPT (0.60) MAPTALDH1A1HSD17B10RXFP1SERPINE1
SCHEMBL420221 0.76 ALDH1A1 (0.68) MAPTALDH1A1GAAHSD17B10SERPINE1
SCHEMBL15712210 0.75 ERBB2 (0.48) MAPTSMN1; SMN2LMNAPOLB
SCHEMBL417918 0.75 MEN1 (0.53) NTSR1GAAHSD17B10KDM4EPOLB
SCHEMBL4484108 0.75 ATM (0.52) MAPTNTSR1ALDH1A1KDM4E
SCHEMBL15712361 0.74 ERBB2 (0.47) NTSR1SERPINE1NR4A2
SCHEMBL416730 0.74 SERPINE1 (0.66) MAPTALDH1A1GAAHSD17B10SERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 MAPT 2976/4885NTSR1 2295/4885ALDH1A1 1450/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 MAPT 2976/4885NTSR1 2295/4885ALDH1A1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.